ExploreWatchlistsPricing
  1. JP-listed companies
  2. Daito Pharmaceutical Co., Ltd.
  3. Financials
  4. Earnings per share

Daito Pharmaceutical Co., Ltd. (4577)

Market cap
¥42.2B
P/E ratio
16.6x
Daito manufactures active pharmaceutical ingredients and prescription drugs for domestic and international pharmaceutical companies. The company offers an integrated production system from raw materials to final formulations.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEarnings per share (JPY)YoY (%)
May 31, 202562.7-70.12%
May 31, 2024210-16.13%
May 31, 2023250.4-25.35%
May 31, 2022335.4+7.84%
May 31, 2021311+0.44%
May 31, 2020309.7+10.31%
May 31, 2019280.7+15.49%
May 31, 2018243.1+14.52%
May 31, 2017212.3+3.51%
May 31, 2016205.1+11.75%
May 31, 2015183.5+10.16%
May 31, 2014166.6-14.19%
May 31, 2013194.1+25.16%
May 31, 2012155.1

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat